Top Biotech Companies in Singapore (91)
ChemLex is a Singapore-based company delivering autonomous chemical synthesis services for the pharmaceutical and biotech industry. Our AI-integrated autonomous synthesis platform improves quality, consistency, and productivity while reducing costs and supporting ESG goals.
In a rapidly changing industry, caregivers remain the constant. Every day they demonstrate their passion for helping people despite unprecedented pressure to increase access and quality of care with the same or fewer resources. Hillrom is driven by patient-centered care. Everything we do, and all our products and technologies, are designed to enhance outcomes for patients and caregivers. It starts...
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture...
Thermo Fisher Scientific's Top Stability & Growth Strengths
Strong Market Position & Advantage: Thermo Fisher’s scale and breadth—largest revenue in 2025 (~$44.6B), leadership across a moderately consolidated tools market, and a top‑tier market value—support clear category leadership. Third‑party benchmarking and peer comparisons (e.g., relative to Danaher) reinforce its platform advantage.
Diversified Revenue Streams: A broad, integrated portfolio spanning instruments, consumables, diagnostics, distribution, and biopharma services (PPD, Patheon) drives multiple revenue engines and customer stickiness. Recurring consumables/services and distribution contribute steady mix that helps smooth cycles.
Innovation-Driven Growth: Recent product launches (e.g., Glacios 3 Cryo‑TEM, TSQ Certis) and the NVIDIA collaboration to accelerate AI‑enabled and increasingly autonomous lab systems indicate continued innovation momentum. These initiatives position the platform to capture next‑gen workflow demand.
AMILI is a precision gut microbiome company based in Singapore, serving the region. Through AMILI's proprietary analytics engine, PRIME, we develop diagnostics tests, predictive algorithms and microbiome-modifying interventions. Our consumer health arm, BIO & ME, utilises insights from AMILI's database and PRIME to generate Asia-centric solutions towards personalised diet, supplementation and precision health. AMILI also houses Southeast Asia's first and...
Systemic Bio is a 3D Systems company based in Houston, Texas, focused on the development of vascularized organ models made out of hydrogels and human cells to be used for drug discovery and development.
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt...
Oxford Nanopore Technologies's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show a meaningful step‑up in 2025 revenue with double‑digit year‑over‑year growth and guidance pointing to continued double‑digit expansion into 2026. Feedback suggests performance was slightly ahead of prior guidance and supported by broad‑based demand across regions and customer segments.
Strong Market Position & Advantage: ONT is described as a clear leader in nanopore sequencing and a co‑leader in long‑reads, differentiated by portability, real‑time analysis, ultra‑long reads, and native DNA/RNA methylation detection. Flagship datasets and assemblies reinforce this positioning.
Market Expansion: Updates highlight accelerating adoption beyond academia into clinical, applied industrial and biopharma use cases, alongside growing high‑throughput deployments on PromethION. Feedback suggests growth was evident across major geographies and end‑markets with notable momentum in regulated and applied settings.
Hoosier Cancer Research Network (HCRN) is an independent nonprofit contract research organization specializing in early-phase, multi-center, investigator-initiated oncology clinical trials, with a mission to advance cancer research, education, and patient advocacy.
NalaGenetics was built with the passion to make preventive, DNA-based precision healthcare accessible to as many people as possible. Specifically, catalyzed by the founders’ personal experiences of problematic medication side effects and knowledge of what genetic testing can offer, NalaGenetics aims to help people achieve better nutrition and prescription medication outcomes by analyzing their unique DNA. Today, NalaGenetics’ solutions are...
4baseCare, an Illumina-backed Company* headquartered in Singapore, is engaged in developing cutting-edge Precision Oncology Solutions using Advanced Genomics and Next-Gen digital health technology. Taking into consideration that the clinical outcome could significantly vary across different populations, we have developed a unique set of indigenous comprehensive cancer gene panels that enables oncologists to choose the optimal precision therapies for their patients. Our...
Anuva is creating the world’s most diverse Genomic Bio/Data Bank to help uncover novel biological pathways for drug discovery. Anuva is a translational research company that is creating the most diverse Genomic Bio/Data Bank of Asian Populations, which is being utilized for research & development within the pharma industry. Our cohorts and biorepository allow for follow-on clinical and translational studies,...
Esco Lifesciences is a world-leading manufacturer and service provider of life science tools. Esco contributes to meeting the challenges of the 21st century with a diverse range of business units—Scientific, Medical, Healthcare, and Aster. The company continuously innovates its products to help clinical and industrial laboratories conduct successful research and development, quality control, and analysis. Esco continues to provide reliable...
ESCO's Top Stability & Growth Strengths
Market Expansion: Public signals indicate the company opened a China headquarters in 2025, brought South Korea sales/service in‑house in 2024, and expanded EU manufacturing with a new Lithuania plant, alongside partnerships that broaden reach. Evidence also highlights sales in 100+ countries and operations spanning 24 countries, pointing to a broad and active commercial footprint.
Investor Backing & Capital Strength: A record-setting, oversubscribed US$200M Series A in 2021 led by Novo Holdings and Vivo Capital signals strong institutional confidence and funding for expansion, M&A, and R&D. Subsequent acquisitions, facility openings, and partnerships align with the stated use of proceeds and reinforce capital-enabled growth.
Strong Market Position & Advantage: Multiple independent market summaries consistently list the company among top global competitors in biosafety cabinets and clean‑air workstations, indicating leadership within that segment. A large installed base and global operations presence reinforce recognition across labs, hospitals, and biopharma.
Syngenta Group is a leading global agricultural technology (AgTech) company headquartered in Basel, Switzerland. With over 50,000 employees across more than 90 countries, it provides farmers with innovative technology and expertise to increase productivity and ensure the growth of healthy, affordable, and sustainable food. The company is a world market leader in sustainable agriculture, offering a diverse portfolio of seeds...
Bio-Rad now offers over 11,000 antibodies and related reagents for various applications such as flow cytometry. We also provide highly validated Precision Ab™ antibodies for western blotting.
Livestock disease prevention and sustainable agri productivity. Singaporean synbio startup funded by EF Venture Capital.
Biomatch specializes in connecting top talent with leading companies in the life sciences sector, including pharmaceuticals, biotechnology, and medical technology. They offer tailored recruitment solutions, conduct candidate assessments, and aim to find the right job match for candidates and experts for companies.
WonderLab is a non-profit organization providing pediatric physical, occupational, and speech therapy services.
For 85 years, PerkinElmer has pushed the boundaries of science from food to health to the environment. We’ve always pursued science with a clear purpose – to help our customers achieve theirs. Our expert team brings technology and intangibles, like creativity, empathy, diligence, and a spirit of collaboration, in equal measure, to fulfill our customers’ desire to work better, innovate...
PerkinElmer's Top Stability & Growth Strengths
Strong Market Position & Advantage: Colleagues are often seen as operating from a top-tier competitive position in applied, food, and environmental analytical markets, including a significant presence in food testing and leadership in multivendor lab services via OneSource. The large global installed base and asset footprint are portrayed as reinforcing defensibility and ongoing demand for services and support.
Innovation-Driven Growth: Colleagues are often seen as sustaining relevance through ongoing product launches and upgrades such as digital PCR systems, updated LIMS software, and new analytical platforms aimed at emerging needs like PFAS detection and battery applications. The continued cadence of new instruments and workflow solutions is positioned as a key growth lever alongside services and consumables.
Investor Backing & Capital Strength: Colleagues are often seen as supported by private-equity ownership under New Mountain Capital and described with a substantial valuation, suggesting access to capital and an explicit mandate to scale. Recent acquisitions (e.g., Covaris and Project Farma) are framed as capability-building moves consistent with a funded expansion strategy.
Umami Bioworks is a marine biotechnology company developing cultivated seafood and other marine-derived biosolutions. Its AI-driven ALKEMYST platform combines genomics, stem cell biology, machine learning, and automation to enable scalable, traceable, cruelty-free production. The company licenses modular systems to manufacturing partners and supports applications in seafood, cosmetics, and nutrition, aiming to reduce overfishing and ecosystem strain while improving sustainable food...
Respiree© is a digital therapeutics company providing personalized healthcare services for chronic cardio-pulmonary disease management using a combination of proprietary breath-cardio sensors, AI and workflow integrated UIUX. The iRIS platform by Respiree© uses data captured from remote-patient-monitors, mobile applications and medical records to longitudinally measure, track disease progression and create reports for physicians and hospitals.
At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical difference and are developed through sustainable environmental, social and governance practices. We’ve been working openly and proactively with clinicians and our partners for almost half a century to advance precision radiation therapy and meet continuously evolving patient needs—no matter where they are in the world. To us, it's personal, and...
Elekta's Top Stability & Growth Strengths
Strong Market Position & Advantage: Elekta is a top-tier radiotherapy vendor with category leadership in cranial stereotactic radiosurgery and a notable presence in high-field MR-guided therapy, reinforcing durable competitive standing. Recognition for oncology information systems further supports its positioning in cancer centers.
Innovation-Driven Growth: Recent launches such as Elekta Evo and the Elekta ONE software suite, alongside continued advancement of Unity MR‑Linac workflows, indicate a pipeline that is aiding orders and improving mix. These innovations underpin adaptive and image‑guided therapy strategies across the portfolio.
Resilient & Sustainable Growth: Book‑to‑bill ratios above 1.0 and low single‑digit constant‑currency sales growth point to steady underlying expansion. Improving adjusted margins in recent quarters suggest operational gains despite macro headwinds.
